Here's Why Seattle Genetics Climbed 17.6% in September
Shares of Seattle Genetics (NASDAQ: SGEN) jumped 17.6% in September, according to data provided by S&P Global Market Intelligence, as the biotech rounded out the month with positive data from a pair of clinical trials presented at the 2019 European Society for Medical Oncology (ESMO) Congress.
In a phase 2 clinical trial, Seattle Genetics' tucatinib combined with Roche's Herceptin produced a response in 52.2% of patients with a specific type of late-stage colorectal cancer. There wasn't a control group that received placebo or an alternative drug, but these patients had already failed two treatments, so over half of the 23 patients responding was quite impressive.
Image source: Getty Images.
Source Fool.com
